Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics
Preprint
Abstract
Protein therapeutics, like peptides and antibodies, have become critical to healthcare. Despite their exceptional potency and specificity, biopharmaceuticals are prone to aggregation, often necessitating low formulation concentrations as well as cold storage and distribution to maintain stability. Yet, high doses are required to treat many diseases. To achieve these doses, most approved protein drug products are administered intravenously, imposing excessive burdens on patients and the healthcare system. New approaches are needed to formulate proteins at high concentrations to enable less burdensome subcutaneous injection, preferably in an autoinjector format. To address this challenge, we report a subcutaneously injectable biotherapeutic delivery platform composed of spray-dried protein microparticles suspended in a non-solvent liquid carrier. These microparticles contain only active biopharmaceutical agent and a high glass transition temperature polyacrylamide-derived copolymer excipient affording several key benefits over traditional excipients, including: (i) improved stabilization of biopharmaceuticals through the spray drying process, and (ii) improved morphology and properties of the spray-dried particles, enhancing suspension injectability. Experiments with albumin and human IgG demonstrate that this technology enables ultra-high-concentration protein formulations (exceeding 500 mg/mL) that are injectable through standard needles with clinically relevant injection forces. Additionally, experiments in mice show these ultra-high-concentration formulations reduce required injection volumes without altering pharmacokinetics. This approach could double the number of commercial protein drugs amenable to subcutaneous administration, dramatically reducing burden and improving access to these critical biopharmaceuticals. One Sentence Summary Here we leverage a unique copolymer excipient to enable ultra-high concentration protein formulations with improved stability and amenable to subcutaneous injection that can reduce patient burden, lower costs, and improve access to critical drugs.Keywords
This publication has 59 references indexed in Scilit:
- Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical DevelopmentClinical Pharmacology & Therapeutics, 2024
- Stable High‐Concentration Monoclonal Antibody Formulations Enabled by an Amphiphilic Copolymer ExcipientAdvanced Therapeutics, 2022
- Challenges and Considerations in Development and Manufacturing of High Concentration Biologics Drug ProductsJournal of Pharmaceutical Innovation, 2019
- Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and OpportunitiesBioDrugs, 2018
- Surface Enrichment and Depletion of the Active Ingredient in Spray Dried Amorphous Solid DispersionsPharmaceutical Research, 2018
- Pharmacokinetics of Monoclonal AntibodiesCPT: Pharmacometrics & Systems Pharmacology, 2017
- Influence of Hydroxypropyl‐Beta‐Cyclodextrin on the Stability of Dilute and Highly Concentrated Immunoglobulin G FormulationsJournal of Pharmaceutical Sciences, 2013
- Investigating High-Concentration Monoclonal Antibody Powder Suspension in Nonaqueous Suspension Vehicles for Subcutaneous InjectionJournal of Pharmaceutical Sciences, 2012
- Trileucine Improves Aerosol Performance and Stability of Spray‐Dried Powders for InhalationJournal of Pharmaceutical Sciences, 2008
- A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibodyJournal of Pharmaceutical Sciences, 2001